TAVI with the ACURATE neo transcatheter heart valve in special populations: A systematic review
TAVI with the ACURATE neo transcatheter heart valve in special populations: A systematic review
Blog Article
The ACURATE neo transcatheter aortic valve is a self-expanding device suitable for both transfemoral and transapical approach, but specific groups of patients are under-represented in clinical trials.We aim to provide a comprehensive systematic review on TAVI with ACURATE neo in those special populations.TAVI in bicuspid aortic valve, TAVI in patients with small aortic annulus, TAVI for pure aortic regurgitation and valve-in-valve procedures, were systematically reviewed.
The primary endpoint was device success as defined by VARC-2 criteria.The secondary endpoints were safety and performance outcomes according to VARC-2 consensus document.ACURATE neo exhibited similar outcomes in bicuspid vs tricuspid aortic valve except for pre and post-dilatation rates in one observational study.
Lower mean aortic gradient and higher pre-dilatation rates with comparable safety click here outcomes were described for ACURATE neo when compared to Lotus and Evolut-R for bicuspid aortic valve stenosis.2 studies compared ACURATE in small aortic annuli.ACURATE neo showed lower transvalvular gradients Sneakers for Men - Grey - Canvas Mesh Athletic Running Shoes and lower patient prosthesis mismatch rates compared to Sapien 3 and when compared to Evolut R/ Evolut PRO/ Portico, results were similar except for pre-dilatation rates.
3 studies investigated ACURATE neo for pure aortic regurgitation and one for valve-in-valve procedure and demonstrated safety and efficacy, with the exception of malposition events in patients designated for higher valve deployment in the valve-in-valve implantation study.ACURATE neo valve may be a feasible and safe option for patients with bicuspid anatomy, small aortic annulus, previously implanted bioprosthetic aortic valve and pure aortic regurgitation.Registration number: Available at https://osf.
io/aus26 (DOI 10.17605/OSF.IO/AUS26).